Effectiveness of Baricitinib in Severe Alopecia Areata in Real Life: A Retrospective Study of 87 Patients

This retrospective study evaluated the effectiveness and safety of baricitinib, an oral JAK inhibitor, in treating severe alopecia areata (AA) in 87 patients over a 52-week period. The results showed that 37.20% of patients achieved a significant reduction in disease severity, as indicated by a SALT score of ≤ 20, with a notable decrease in overall SALT scores (p < 0.001). Additionally, 72.40% of patients experienced mild or no adverse events, and no serious adverse events were reported. The study concludes that baricitinib is both effective and well-tolerated for managing severe AA in a real-world setting.